The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
Medical Review: A US-licensed physician reviews your profile and prescribes your starting dose
Influence of melatonin and its precursor L-tryptophan on Th1 dependent contact hypersensitivity
From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection
Your pants size, belt notches, and how your clothes fit often reflect fat loss more accurately than your weight in these scenarios
From skin thinning and steroid acne to rebound darkening and mercury toxicity, the list of steroid whitening cream side effects is long and alarming
